Soluble fiber from whole grains and vegetables slows stomach emptying and promotes the gradual release of satiety signals, which overlaps with what GLP-1 medications do
Once a multiple-dose vial is punctured, it should be assigned a "beyond-use" date
However, baseline and periodic testing may be appropriate for those with pre-existing liver disease, metabolic syndrome, obesity with metabolic risk factors, or unexplained elevated liver enzymes
The downsides: portions are small even by GLP-1 standards, subscription is required, and shipping is $19.95 per order
The mechanistic hypothesis: Semaglutide activates GLP-1R, appetite suppression, glycemic control Cagrilintide activates amylin receptors, appetite suppression via the area postrema, slowing of gastric evacuation Two independent mechanisms of appetite suppression a supra-additive effect In Phase 1b and Phase 2 trials the combination showed a stronger effect than either component alone : Semaglutide alone: 14.9 % (STEP-1) Cagrilintide alone (Phase 2): 10.8 % CagriSema combination (Phase 2): 15.6 % CagriSema Phase 3 (REDEFINE 1): 25.3 % CagriSema thus becomes the largest body-weight signal reported in the published incretin literature to date , stronger than Tirzepatide (22.5 % in SURMOUNT-1) and comparable to Retatrutide